Efficacy Highlighted In Fianlimab Cemiplimab In Pretreated Advanced Ccrcc Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma. We present safety and clinical activity data from a phase 1 study (nct03005782) in patients with clear cell renal cell carcinoma (ccrcc) treated with anti–lag 3 (fianlimab) anti–pd 1 (cemiplimab).
Fianlimab Plus Cemiplimab Yields Early Efficacy Signs In Pretreated The combination of fianlimab and cemiplimab rwlc (libtayo) generated well tolerated and durable responses, according to findings from a phase 1 trial (nct03005782) that evaluated pretreated patients with advanced clear cell renal carcinoma (ccrcc). Here, we present an efficacy analysis by bicr in subgroups of pts with adv mel (neoadjuvant adjuvant pretreated [nap], elevated ldh, braf status, adrenal insufficiency [ai], and ctdna status). Here, we report prespecified final analyses of the dose escalation part of a first in human, phase 1 study (nct03005782) of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies. A new study recently published on clinical cancer research shows an acceptable safety and preliminar antitumor activity for fianlimab, an antilymphocyte activation gene 3 antibody (anti lag 3), in monotherapy or in combination with the anti pd 1 cemiplimab in patients with advanced malignancies.
Fianlimab Plus Cemiplimab Yields Early Efficacy Signs In Pretreated Here, we report prespecified final analyses of the dose escalation part of a first in human, phase 1 study (nct03005782) of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies. A new study recently published on clinical cancer research shows an acceptable safety and preliminar antitumor activity for fianlimab, an antilymphocyte activation gene 3 antibody (anti lag 3), in monotherapy or in combination with the anti pd 1 cemiplimab in patients with advanced malignancies. We report results from a first in human phase i study of fianlimab and cemiplimab safety and efficacy in various malignancies including advanced melanoma. In a multicohort trial (nct03005782), fianlimab cemiplimab demonstrated reproducibly high clinical activity (objective response rate [orr] 61%; n=98) in three independent cohorts of pts with advanced pd l1 naïve metastatic melanoma, with an acceptable safety profile. Here, we report prespecified final analyses of the dose escalation part of a first in human, phase 1 study (nct03005782) of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies. In this first in human study, the combination of fianlimab and cemiplimab yielded high clinical activity in patients with advanced melanoma who had not received previous anti–pd 1 therapy in the setting of advanced disease.
Fianlimab Plus Cemiplimab Shows Efficacy In Pd 1 Pretreated Metastatic We report results from a first in human phase i study of fianlimab and cemiplimab safety and efficacy in various malignancies including advanced melanoma. In a multicohort trial (nct03005782), fianlimab cemiplimab demonstrated reproducibly high clinical activity (objective response rate [orr] 61%; n=98) in three independent cohorts of pts with advanced pd l1 naïve metastatic melanoma, with an acceptable safety profile. Here, we report prespecified final analyses of the dose escalation part of a first in human, phase 1 study (nct03005782) of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies. In this first in human study, the combination of fianlimab and cemiplimab yielded high clinical activity in patients with advanced melanoma who had not received previous anti–pd 1 therapy in the setting of advanced disease.
Comments are closed.